American Society of Hematology 2025


Preview oral and poster presentations shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in Orlando, FL on Dec. 5-9th, 2025.

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study Video

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia
Jorge Castillo, MD

Jorge Castillo, MD

Medical Oncology
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study Video

Andrew A. Lane, MD, PhD discuss results from a phase 2 Study

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)
Andrew Lane, MD, PhD

Andrew Lane, MD, PhD

Medical Oncology
Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study Video

Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study

Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning
Mahasweta Gooptu, MD

Mahasweta Gooptu, MD

Medical Oncology
Reid W. Merryman, MD discusses results of a multicenter phase II trial Video

Reid W. Merryman, MD discusses results of a multicenter phase II trial

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Reid Merryman, MD

Reid Merryman, MD

Medical Oncology
Omar Nadeem, MD discusses results of the Phase II d-PRISM study Video

Omar Nadeem, MD discusses results of the Phase II d-PRISM study

Daratumumab in high-rish MGUS and low-risk smoldering myeloma
Omar Nadeem, MD

Omar Nadeem, MD

Medical Oncology
Jennifer Brown, MD, PhD discusses results form the ALPINE trial Video

Jennifer Brown, MD, PhD discusses results form the ALPINE trial

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Jennifer Brown, MD, PhD

Jennifer Brown, MD, PhD

Medical Oncology
Jacqueline Garcia, MD discussed results from the Phase # VERONA study Video

Jacqueline Garcia, MD discussed results from the Phase # VERONA study

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)
Jacqueline Garcia, MD

Jacqueline Garcia, MD

Medical Oncology
Austin Kim, MD discusses phase I/II study Video

Austin Kim, MD discusses phase I/II study

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Austin Kim, MD

Austin Kim, MD

Medical Oncology
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial Video

Marlise Luskin, MD, MSCE discusses results of a phase 1 trial

Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Marlise Luskin, MD, MSCE

Marlise Luskin, MD, MSCE

Medical Oncology
Shayna Sarosiek, MD discusses WM-NET 1 trial Video

Shayna Sarosiek, MD discusses WM-NET 1 trial

Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Shayna Sarosiek, MD

Shayna Sarosiek, MD

Medical Oncology

News Releases



CME

 

Subscribe

 

Follow us on social media

 

Dana-Farber Physician-Scientists Presentation Schedule